113 HR 2003 IH: Gluten in Medicine Disclosure Act of 2013 U.S. House of Representatives 2013-05-15 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I 113th CONGRESS 1st Session H. R. 2003 IN THE HOUSE OF REPRESENTATIVES May 15, 2013 Mr. Ryan of Ohio (for himself and Mrs. Lowey) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to require the label of drugs intended for human use to contain a parenthetical statement identifying the source of any ingredient constituting or derived from a grain or starch-containing ingredient.

1.

Short title

This Act may be cited as the Gluten in Medicine Disclosure Act of 2013.

2.

Labeling of source of human drug ingredients constituting or derived from a grain or starch-containing ingredient

(a)

Misbranding

Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following: (bb)If it is a drug— (1)that is intended for human use; (2)that contains an ingredient (other than a polyol) that constitutes or is derived from a grain or starch-containing ingredient; and (3)whose label fails to include a parenthetical statement identifying the source of the ingredient so constituted or derived. . (b)

Applicability

Section 502(bb) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a) of this section, shall apply beginning on the sooner of— (1)a date to be determined by the Secretary of Health and Human Services; and (2)the date that is 2 years after the date of the enactment of this Act.